Defucosylated Mouse–Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors

The epidermal growth factor receptor (EGFR) contributes to tumor malignancy via gene amplification and protein overexpression. Previously, we developed an anti-human EGFR (hEGFR) monoclonal antibody, namely EMab-134, which detects hEGFR and dog EGFR (dEGFR) with high sensitivity and specificity. In this study, we produced a defucosylated mouse–dog chimeric anti-EGFR monoclonal antibody, namely E134Bf. In vitro analysis revealed that E134Bf highly exerted antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against a canine osteosarcoma cell line (D-17) and a canine fibroblastic cell line (A-72), both of which express endogenous dEGFR. Moreover, in vivo administration of E134Bf significantly suppressed the development of D-17 and A-72 compared with the control dog IgG in mouse xenografts. These results indicate that E134Bf exerts antitumor effects against dEGFR-expressing canine cancers and could be valuable as part of an antibody treatment regimen for dogs.

[1]  M. Kawada,et al.  Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 134-mG2a-f Exerts Antitumor Activities in Mouse Xenograft Models of Dog Epidermal Growth Factor Receptor-Overexpressed Cells. , 2021, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[2]  M. Kawada,et al.  An Anti-HER2 Monoclonal Antibody H2Mab-41 Exerts Antitumor Activities in Mouse Xenograft Model Using Dog HER2-Overexpressed Cells. , 2021, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[3]  H. Harada,et al.  Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma , 2021, Oncology reports.

[4]  H. Harada,et al.  An anti-TROP2 monoclonal antibody TrMab-6 exerts antitumor activity in breast cancer mouse xenograft models , 2021, Oncology reports.

[5]  T. Nakagawa,et al.  Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma , 2020, Cells.

[6]  M. Kawada,et al.  The anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody EpMab-16 exerts antitumor activity in a mouse model of colorectal adenocarcinoma , 2020, Oncology letters.

[7]  H. Harada,et al.  Anti-EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas , 2020, Oncology reports.

[8]  M. Kawada,et al.  A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma , 2020, Biochemistry and biophysics reports.

[9]  M. Kawada,et al.  Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies. , 2020, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[10]  M. Kawada,et al.  Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation , 2020, International journal of molecular sciences.

[11]  H. Harada,et al.  A defucosylated anti-CD44 monoclonal antibody 5-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma , 2020, Oncology reports.

[12]  H. Harada,et al.  Anti-EGFR monoclonal antibody 134-mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma , 2020, International journal of molecular medicine.

[13]  M. Igase,et al.  Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment , 2020, Scientific Reports.

[14]  H. Harada,et al.  H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts , 2020, Experimental and therapeutic medicine.

[15]  P. Viola.  The biology of Epidermal Growth Factor Receptor (EGFR) from regulating cell cycle to promoting carcinogenesis: the state of art including treatment options , 2020 .

[16]  M. Kawada,et al.  Antibody–Drug Conjugates Using Mouse–Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model , 2020, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[17]  H. Harada,et al.  A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity , 2020, Oncology letters.

[18]  Zhen Huang,et al.  Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma , 2019, Scandinavian journal of clinical and laboratory investigation.

[19]  Ê. Ferreira,et al.  Quantification of EGFR family in canine mammary ductal carcinomas in situ: implications on the histological graduation , 2019, Veterinary Research Communications.

[20]  M. Martano,et al.  Canine oral fibrosarcoma: Changes in prognosis over the last 30 years? , 2018, Veterinary journal.

[21]  D. O'Neill,et al.  Longevity and mortality in Kennel Club registered dog breeds in the UK in 2014 , 2018, Canine Genetics and Epidemiology.

[22]  F. Bazer,et al.  Myricetin treatment induces apoptosis in canine osteosarcoma cells by inducing DNA fragmentation, disrupting redox homeostasis, and mediating loss of mitochondrial membrane potential , 2018, Journal of cellular physiology.

[23]  Sheng-lin Wang,et al.  Prognostic significance of the expression of HER family members in primary osteosarcoma , 2018, Oncology letters.

[24]  H. Harada,et al.  Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma , 2018, Oncotarget.

[25]  I. Miller,et al.  Comparative proteome analysis of monolayer and spheroid culture of canine osteosarcoma cells. , 2018, Journal of proteomics.

[26]  I. Tannock,et al.  Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. , 2018, Cancer treatment reviews.

[27]  H. Harada,et al.  Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity , 2017, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[28]  N. Mongan,et al.  Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics , 2017, Acta Veterinaria Scandinavica.

[29]  Kai Li,et al.  Epidermal growth factor receptor in glioblastoma , 2017, Oncology letters.

[30]  L. Ginaldi,et al.  17-AAG and Apoptosis, Autophagy, and Mitophagy in Canine Osteosarcoma Cell Lines , 2017, Veterinary pathology.

[31]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[32]  K. Ohashi,et al.  Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma , 2016, PloS one.

[33]  C. Löhr,et al.  Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro , 2016, BMC Veterinary Research.

[34]  A. Mutsaers,et al.  Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells , 2016, BMC Veterinary Research.

[35]  R. Simpson,et al.  Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation , 2016, Oncotarget.

[36]  Rui Zhang,et al.  The effect of Zhangfei/CREBZF on cell growth, differentiation, apoptosis, migration, and the unfolded protein response in several canine osteosarcoma cell lines , 2015, BMC Veterinary Research.

[37]  R. Lechowski,et al.  What do we know about canine osteosarcoma treatment? – review , 2014, Veterinary Research Communications.

[38]  F. Rossi,et al.  EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival. , 2014, Veterinary and comparative oncology.

[39]  T. Stockner,et al.  Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients , 2014, Molecular Cancer Therapeutics.

[40]  J. Schlessinger,et al.  The EGFR family: not so prototypical receptor tyrosine kinases. , 2014, Cold Spring Harbor perspectives in biology.

[41]  D. Thamm,et al.  Comparison of Carboplatin and Doxorubicin‐Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma , 2014, Journal of veterinary internal medicine.

[42]  G. Ogilvie,et al.  Characterization and evaluation of a new oncolytic Vaccinia Virus strain LIVP6.1.1 for canine cancer therapy , 2013, Bioengineered.

[43]  G. T. Selvarajah,et al.  Expression of epidermal growth factor receptor in canine osteosarcoma: association with clinicopathological parameters and prognosis. , 2012, Veterinary journal.

[44]  T. Stockner,et al.  Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting , 2012, Molecular immunology.

[45]  A. Scott,et al.  Monoclonal antibody dose determination and biodistribution into solid tumors. , 2011, Therapeutic delivery.

[46]  M. Stalker,et al.  Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006). , 2011, Journal of the American Veterinary Medical Association.

[47]  N. Ridgway,et al.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. , 2011, Journal of thoracic disease.

[48]  J. Wood,et al.  Methods and mortality results of a health survey of purebred dogs in the UK. , 2010, The Journal of small animal practice.

[49]  B. Powers,et al.  Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. , 2009, Journal of the American Animal Hospital Association.

[50]  B. Peters,et al.  Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. , 2007, Human pathology.

[51]  W. Winkelmann,et al.  Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome , 2007, Clinical Cancer Research.

[52]  F. Millanta,et al.  The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. , 2006, Research in veterinary science.

[53]  S. Withrow,et al.  Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004). , 2006, Journal of the American Veterinary Medical Association.

[54]  S. Fosmire,et al.  CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma , 2005, Veterinary pathology.

[55]  G Milano,et al.  Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  J. Berg.  Canine osteosarcoma: amputation and chemotherapy. , 1996, The Veterinary clinics of North America. Small animal practice.

[57]  W. Rand,et al.  Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. , 1995, Journal of the American Veterinary Medical Association.

[58]  S. George,et al.  Intra‐arterial cisplatin with or without radiation in limb‐sparing for canine osteosarcoma , 1993, Cancer.

[59]  L. Binn,et al.  Establishment of a canine cell line: derivation, characterization, and viral spectrum. , 1980, American journal of veterinary research.

[60]  J. Riggs,et al.  Immunofluorescent studies of RD-114 virus replication in cell culture. , 1974, The Journal of general virology.